RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study.

PURPOSE: Radiation-induced sarcoma (RIS) is a rare but serious event. Its occurrence has been discussed during the implementation of new radiation techniques and justified appropriate radioprotection requirements. New approaches targeting intrinsic radio-sensitivity have been described, such as radiation-induced CD8 T-lymphocyte apoptosis (RILA) able to predict late radio-induced toxicities. We studied the role of RILA as a predisposing factor for RIS as a late adverse event following radiation therapy (RT). PATIENTS AND METHODS: In this prospective biological study, a total of 120 patients diagnosed with RIS were matched with 240 control patients with cancer other than sarcoma, for age, sex, primary tumor location and delay after radiation. RILA was prospectively assessed from blood samples using flow cytometry. RESULTS: Three hundred and forty-seven patients were analyzed (118 RIS patients and 229 matched control patients). A majority (74%) were initially treated by RT for breast cancer. The mean RT dose was comparable with a similar mean (± standard deviation) for RIS (53.7 ±â€¯16.0 Gy) and control patients (57.1 ±â€¯15.1 Gy) (p = .053). Median RILA values were significantly lower in RIS than in control patients with respectively 18.5% [5.5-55.7] and 22.3% [3.8-52.2] (p = .0008). Thus, patients with a RILA >21.3% are less likely to develop RIS (p < .0001, OR: 0.358, 95%CI [0.221-0.599]. CONCLUSION: RILA is a promising indicator to predict an individual risk of developing RIS. Our results should be followed up and compared with molecular and genomic testing in order to better identify patients at risk. A dedicated strategy could be developed to define and inform high-risk patients who require a specific approach for primary tumor treatment and long term follow-up.

[Radiotherapy after prostatectomy: experiences in Luxembourg from 2005 to 2006]. / Radiothérapie après prostatectomie: expérience au Luxembourg de 2005 a 2006.

Radical prostatectomy is a therapeutic option for the treatment of localized prostate cancer (T1 and T2). The prognostic factors which define risks of recurrence after prostatectomy are: capsular invasion, invasion of resection margins, seminal vesicle invasion. Two randomized trials show that adjuvant radiotherapy improves local control and biochemical recurrence-free survival. Between 2005 and 2006, 12 patients of Centre François Baclesse have been irradiated on theprostatic loge. Immediate post-operative radiotherapy was preferably used. Late toxicity (grade 1) occurred only in one patient (1 case out of 8). Based on the literature, immediate postoperative irradiation is preferentially proposed in case of unfavourable factors, or possibly used secondly, in case of biological recurrence (in early situation i.e. PSA < 0.5).

[Localized prostatic cancer: treatment exclusive by radiotherapy guided by imagery, experiences in Luxembourg in 2005 and 2006]. / Cancer localisé de la prostate: traitement par radiothérapie exclusive guideée par l'imagerie, expérience au Luxembourg en 2005 et 2006.

Exclusive radiotherapy is one of therapeutic standard in the curative treatment of localized prostate cancer. Results are equivalent when compared with other treatment regimens (radical prostatectomy or curietherapy) in localized forms. However, the patients risks profiles to predict noxious effects are different. Between 2005 and 2006, 27 patients have been treated with intensity modulated radiation therapy and image-guided radiotherapy (IGRT), after implantation of gold markers to target prostate localization during daily radiotherapy seances. The total dose of radiation delivered in prostate is 74 Gy with respect to the maximal dose defined to the rectum and to the bladder. Late toxicity was limited to grade 2 (rectitis and cystitis). These symptoms were temporary. One patient out of 20 patients with one-year follow-up experienced biological recurrence with metastasis progression. New radiotherapy technologies have allowed to reduce the incidence of the toxicity especially late rectal toxicity (2.2% in 2006) within a limited time period (one-year minimum).

High dose rate brachytherapy with customized applicators for malignant facial skin lesions.

PURPOSE: Brachytherapy is a well-known treatment in the management of skin tumors. For facial or scalp lesions, applicators have been developed to deliver non-invasive treatment. We present cases treated with customized applicators with high dose rate system. MATERIAL AND METHODS: Patients with poor performance status treated for malignant skin lesions of the scalp or the facial skin between 2011 and 2014 were studied. Afterloading devices were chosen between Freiburg(®) Flap, silicone-mold or wax applicators. The clinical target volume (CTV) was created by adding margins to lesions (10mm to 20mm). The dose schedules were 25Gy in five fractions for postoperative lesions, 30Gy in six fractions for exclusive treatments and a single session of 8Gy could be considered for palliative treatments. RESULTS: In 30 months, 11 patients received a treatment for a total of 12 lesions. The median age was 80 years. The median follow-up was 17 months and the 2-year local control rate was 91%. The mean CTV surface was 41.1cm(2) with a mean thickness of 6.1mm. We conceived three wax applicators, used our silicone-mold eight times and the Freiburg(®) Flap one time. We observed only low-grade radiodermitis (grade I: 50%, grade II: 33%), and no high-grade skin toxicity. CONCLUSION: High dose rate brachytherapy with customized applicators for facial skin and scalp lesions is efficient and safe. It is a good modality to treat complex lesions in patients unfit for invasive treatment.

[Dosimetric comparaison between VMAT and tomotherapy with para-aortic irradiation for cervix carcinoma]. / Comparaison entre arcthérapie volumétrique modulée et tomothérapie pour le cancer du col utérin, avec irradiation lomboaortique.

PURPOSE: Intensity-modulated radiotherapy (IMRT) has proven its dosimetric superiority over conformational radiotherapy for cervix cancers in terms of digestive toxicity. Volumetric modulated arctherapy (VMAT) has shown its dosimetric interest when compared to IMRT with static beams. The purpose of our study was to compare conformational radiotherapy, VMAT and tomotherapy for cervical cancers with para-aortic lymph nodes irradiation. PATIENTS AND METHODS: The dosimetric data from ten patients were compared between the three techniques, with collection of the dose received by the planning target volume, kidneys, bowel, rectum, bladder, bone marrow and spinal cord, as well as the complete dose. RESULTS: There was a significant difference in favour of VMAT and tomotherapy when compared with conformational radiotherapy for the organs at risk: intestines (V(20 Gy), V(30 Gy) and V(45 Gy)), rectum (V(30 Gy) and V(45 Gy)), bladder (V(30 Gy) and V(45 Gy)) and kidneys (V(12 Gy), Daverage, V(20 Gy)). Volumes receiving 20, 30 and 45 Gy were significantly higher in conformational radiotherapy than in VMAT and tomotherapy. There was a significant difference in favour of tomotherapy when compared with VMAT for V(12 Gy) in kidneys and V(45 Gy) in the bladder. CONCLUSION: This study confirms the interest of VMAT and tomotherapy for pelvic and para-aortic lymph nodes irradiation of cervix cancer when compared with conformational radiotherapy. There was little difference between VMAT and tomotherapy, except for kidney sparing, which was better with tomotherapy and thus may be interesting for patients receiving nephrotoxic chemotherapy.

Implantation of fiducial markers in the liver for stereotactic body radiation therapy: Feasibility and results.

PURPOSE: Robotic stereotactic body radiation therapy (SBRT) for the treatment of hepatocellular carcinoma requires the perilesional implant of gold fiducial markers for detection by scopy. The purpose of this study is to determine whether the implant of gold fiducial markers is still possible and, if so, with which imaging technique and with what results. MATERIALS AND METHODS: This is a prospective study based on the implant of fiducial markers in the liver in our department for a treatment by SBRT for a hepatocellular carcinoma in 38 patients (49 lesions to treat) over a period of one year. As the first choice, it consisted of sonographic guidance and, if not possible, CT-scan guidance was used. RESULTS: The mean number of fiducial markers implanted per procedure was 2.68(±0.61) with almost exclusive sonographic guidance (36 out of 38 patients or 95% of the patients). The mean distance between the markers and the lesion was 32mm (±11mm) and that between the markers was 17mm (±7mm). CONCLUSION: SBRT is being evaluated for the treatment of liver lesions. The radiologist has an important role to play since the implant of fiducial markers in the liver is indispensable. It is almost always possible with sonographic guidance, including for lesions not accessible to microbiopsies, a treatment by radiofrequency or for lesions poorly individualisable by sonography or CT-scan.

[Intensity modulated radiotherapy for head and neck cancers: ethics and patients selection]. / Radiothérapie conformationnelle avec modulation d'intensité dans les cancers de la sphère ORL : éthique et sélection des patients.

PURPOSE: Intensity modulated radiotherapy (IMRT) allows a better coverage of the target volume and a better saving of organs at risk with a decrease of toxicity in head and neck cancers. It requires more human labor and materials compared to conformational radiotherapy. If they are insufficient, a selection of the patients receiving IMRT may be necessary, raising an ethical problem. MATERIAL AND METHODS: We collected the motives guiding the choice of the technique of radiotherapy for head and neck cancers during a month of physicists' shortage. RESULTS: Nineteen patients received IMRT and eight conformational radiotherapy. Conformational irradiation was chosen in palliative and postsurgery treatments, to reduce delay, in laryngeal tumors and re-irradiation. IMRT was preferred for complex target volumes and the localizations at risk of important xerostomia following conformational radiotherapy. These choices were confronted with the bioethics criteria of Beauchamp and Childress. The beneficence justified the use of IMRT or conformational radiotherapy depending on the circumstances. The non-maleficence attempted to decrease the toxicity with IMRT. Justice was questioned by the selection. The autonomy of patients was not totally respected in the choice. CONCLUSION: To help in the choice of the patients receiving an IMRT in a crisis situation, we proposed a hierarchical organization of selection criteria: complex volumes close to critical organs at risk, localization with high risk of xerostomia, long life expectancy and postoperative delay constraints.

[Dosimetric comparison between the intensity modulated radiotherapy with fixed field and Rapid Arc of cervix cancer]. / Comparaison dosimétrique des radiothérapies conformationnelles avec modulation d'intensité par faisceaux statiques et RapidArc(®) des cancers du col.

PURPOSE: Concurrent radiochemotherapy is the standard treatment for locally advanced cervical cancer. This treatment is responsible for bowel and hematologic toxicities. The use of intensity-modulated radiotherapy (IMRT), in static beams, allows a decrease of this toxicity. The technique of RapidArc(®) IMRT could lower the dose delivered to the organs at risk and improve the homogeneity of the planning target volume coverage, while decreasing the processing time. PATIENTS AND MATERIALS: For 20 patients, treatment plans performed with IMRT and RapidArc(®) were compared. The target volumes were: the clinical target volume (gross tumour volume, uterus, upper third of the vagina, the hypogastric, iliac and presacral nodal regions), and the planning target volume (clinical target volume+1cm). The delineated organs at risk were: rectum, bladder, bowel and bone marrow. The dose was 45 Gy in 25 fractions. IMRT were delivered with five beams and RapidArc(®) with two arcs. The comparisons were made by the non-parametric test of Wilcoxon. RESULTS: Medium coverage of the planning target volume was better with RapidArc(®) (P=0.01). It was also better regarding the sparing of bowel (P=0.01) and IMRT was better regarding the sparing of bladder (P=0.01) and rectum (P=0.05). The total volume receiving 20 Gy was less important with RapidArc(®) (P<0.001). RapidArc(®) allowed to decrease the treatment time (3 versus 12 minutes with IMRT) and the number of monitor units (MU) (376.5 versus 962.2, on average, P=0.0001). CONCLUSION: The technique of RapidArc(®) seems to obtain better dosimetric results compared to RCMI, with fewer MU, and a significant decrease in treatment time.

[Imaging follow-up of soft tissue sarcomas]. / Intérêt de l'imagerie dans la surveillance des sarcomes des parties molles des membres.

PURPOSE: We have studied the post-treatment follow-up of patients with history of limb soft tissue sarcoma including MR imaging to determine its added value compared to simple clinical follow-up and the impact of MR imaging findings on patient management. We have also studied the value of chest CT to detect metastases. PATIENTS AND METHODS: Retrospective study of 85 patients treated for limb soft tissue sarcoma with post-treatment MR imaging of the affected region. We have studied the percentage of local recurrences and the modality of detection of these recurrences. We have evaluated the impact on management of patients with abnormalities detected on MRI. For distant metastases, we have recorded their percentage and date of occurrence. RESULTS: There were five cases of local recurrence, for a percentage of 6%, with 50% detected clinically. The percentage of metastases was 26%. Six biopsies were performed and complementary examinations were performed in 18 cases based on abnormalities detected on MR. CONCLUSION: These results are in keeping with recommendations from the Fédération nationale des centres de lutte contre le cancer. Imaging is necessary to detect lung metastases.